Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial

Open access

Abstract

BACKGROUND: Pharmacologic treatment options for posttraumatic stress disorder (PTSD) are limited in number and effectiveness. Medications currently in use to treat PTSD were originally approved based on their efficacy in other disorders, such as major depression. Substantial research in PTSD suggests that increased activity of corticotropin releasing hormone (CRH)-containing circuits are involved in the pathophysiology of the disease. This Phase II trial aims to evaluate the efficacy of a CRH type 1 receptor (CRHR1) antagonist in the treatment of PTSD. METHODS/DESIGN: Currently untreated adult women, ages 18 to 65 years, with a primary psychiatric diagnosis of PTSD of at least 3 months' duration, are being enrolled in a parallel-group, double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of GSK561679, a novel CRHR1 receptor antagonist. GSK561679 (or matching placebo) is prescribed at a fixed dose of 350 mg nightly for six weeks. The primary trial hypothesis is that GSK561679 will reduce symptoms of PTSD, as measured by the Clinician-Administered PTSD Scale (CAPS), significantly more than placebo after six weeks of treatment. Putative biological markers of PTSD which may influence treatment response are measured prior to randomization and after five weeks' exposure to the study medication, including: fear conditioning and extinction using psychophysiological measures; variants of stress-related genes and gene expression profiles; and indices of HPA axis reactivity. In addition, the impact of PTSD and treatment on neuropsychological performance and functional capacity are assessed at baseline and after the fifth week of study medication. After completion of the six-week double blind treatment period, subjects enter a one-month follow-up period to monitor for sustained response and resolution of any adverse effects. DISCUSSION: Considerable preclinical and human research supports the hypothesis that alterations in central nervous system CRH neuronal activity are a potential mediator of PTSD symptoms. This study is the first to assess the efficacy of a specific antagonist of a CRH receptor in the treatment of PTSD. Furthermore, the biological and neuropsychological measures included in this trial will substantially inform our understanding of the mechanisms of PTSD. TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT01018992.Registered 6 November 2009. First patient randomized 14 January 2010.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1745-6215-15-240

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Research works printed but not linked: 1

  1. First MB, Spitzer RL, Gibbon M, Williams JB: SCID-I/P, Version 20th edition. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient. 1995, New York: Biometrics Research Department, New York State Psychiatric Institute

Cited by

See all 45

Metadata

Authors
Dunlop, B. W., Rothbaum, B. O., Binder, E. B., Duncan, E., Harvey, P. D., Jovanovic, T., Kelley, M. E., Kinkead, B., Kutner, M., Iosifescu, D. V., Mathew, S. J., Neylan, T. C., Kilts, C. D., Nemeroff, C. B., & Mayberg, H. S.
Affiliations
  • Emory University (US)
  • University of Miami (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Michael E. DeBakey VA Medical Center (US)
  • San Francisco VA Medical Center (US)
  • University of Arkansas for Medical Sciences (US)
Corresponding author
Dunlop, Boadie W
Venue
Trials
Published
2014-06-21
Volume
15
Issue
1
Pages
240-240
ISSN
1745-6215 (ISSN-L)
OpenAlex
W2130017328
Cited by
45
References
54
Citations by year
2026: 2 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 6 · 2017: 6 · 2016: 7 · 2015: 4 · 2014: 2
FWCI
7.50
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Trials (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion)
  • Max Planck Digital Library (submittedVersion, other-oa)
Funders
  • U.S. Department of Veterans Affairs
  • GlaxoSmithKline
  • Neurocrine Biosciences
  • National Institutes of Health (5u19mh069056-10)
  • Clinical Science Research and Development
  • National Institute of Mental Health (U19-MH069056, K23MH086690)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Social Sciences › Psychology › Clinical Psychology › Migration, Health and Trauma
Keywords
post-traumatic stress disorder, women, fear conditioning, fear extinction, stress-related genes, gene expression, HPA axis reactivity, neuropsychological performance, functional capacity, PTSD pharmacotherapy
MeSH terms
CRF Receptor, Type 1, Adolescent, Adult, Aged, Clinical Protocols, Conditioning, Psychological, Diagnostic Techniques, Endocrine, Double-Blind Method, Extinction, Psychological, Fear, Female, Hormone Antagonists, Humans, Hypothalamo-Hypophyseal System, Middle Aged, Oxadiazoles, Pituitary-Adrenal System, Psychiatric Status Rating Scales, Research Design, Stress Disorders, Post-Traumatic, Time Factors, United States, Treatment Outcome, Receptors, Corticotropin-Releasing Hormone, Gene Expression Profiling, Azabicyclo Compounds, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/1745-6215-15-240
The paper
Dunlop, B. W., Rothbaum, B. O., Binder, E. B., Duncan, E., Harvey, P. D., Jovanovic, T., Kelley, M. E., Kinkead, B., Kutner, M., Iosifescu, D. V., Mathew, S. J., Neylan, T. C., Kilts, C. D., Nemeroff, C. B., & Mayberg, H. S. (2014). Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/1745-6215-15-240

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.